{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:35:16Z","timestamp":1791588916437,"version":"4.3.4"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RA 1026\/3-1"],"award-info":[{"award-number":["RA 1026\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01383","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T09:09:32Z","timestamp":1561108172000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":103,"title":["Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases"],"prefix":"10.3389","volume":"10","author":[{"given":"Bernhard F.","family":"Gibbs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Patsinakidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Raap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.neuroscience.2006.07.009","article-title":"Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns","volume":"142","author":"Bando","year":"2006","journal-title":"Neuroscience"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.4049\/jimmunol.1101044","article-title":"Dendritic cells activated by IFN-gamma\/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment","volume":"188","author":"Horejs-Hoeck","year":"2012","journal-title":"J Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1398-9995.2011.02545.x","article-title":"Functional effects of interleukin 31 in human primary keratinocytes","volume":"66","author":"Kasraie","year":"2011","journal-title":"Allergy."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/jid.2015.106","article-title":"IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31","volume":"135","author":"Kunsleben","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/j.1398-9995.2009.02255.x","article-title":"Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins","volume":"65","author":"Kasraie","year":"2010","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cea.12875","article-title":"Human basophils are a source of - and are differentially activated by - IL-31","volume":"47","author":"Raap","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"36673","DOI":"10.1074\/jbc.M607005200","article-title":"Molecular and functional characterization of a soluble form of oncostatin M\/interleukin-31 shared receptor","volume":"281","author":"Diveu","year":"2006","journal-title":"J Biol Chem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1074\/jbc.M609655200","article-title":"Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells","volume":"282","author":"Chattopadhyay","year":"2007","journal-title":"J Biol Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/gut.2006.118679","article-title":"Interleukin 31 mediates MAP kinase and STAT1\/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease","volume":"56","author":"Dambacher","year":"2007","journal-title":"Gut."},{"key":"B11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cytogfr.2008.08.003","article-title":"Structures and biological functions of IL-31 and IL-31 receptors","volume":"19","author":"Zhang","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1517\/14728214.2015.1051964","article-title":"Emerging drugs for the treatment of pruritus","volume":"20","author":"St\u00e4nder","year":"2015","journal-title":"Expert Opin Emerg Drugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0161877","DOI":"10.1371\/journal.pone.0161877","article-title":"IL-31-driven skin remodeling involves epidermal cell proliferation and thickening that lead to impaired skin-barrier function","volume":"11","author":"Singh","year":"2016","journal-title":"PLoS ONE"},{"key":"B15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejphar.2005.04.040","article-title":"Expression of IL-31 gene transcripts in NC\/Nga mice with atopic dermatitis","volume":"516","author":"Takaoka","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1600-0625.2008.00766.x","article-title":"Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC\/Nga mice: a model of atopic dermatitis","volume":"18","author":"Grimstad","year":"2009","journal-title":"Exp Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2741\/s203","article-title":"Pathogenetic and therapeutic implications of the histamine H4 receptor in inflammatory skin diseases and pruritus","volume":"3","author":"Gutzmer","year":"2011","journal-title":"Front Biosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.jaci.2018.07.047","article-title":"Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis","volume":"143","author":"Werfel","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14207","article-title":"The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jaci.2013.03.050","article-title":"Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation","volume":"132","author":"Stott","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1159\/000481609","article-title":"Basophil recruitment to skin lesions of patients with systemic lupus erythematosus mediated by CCR1 and CCR2","volume":"43","author":"Pan","year":"2017","journal-title":"Cell Physiol Biochem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2016.12.989","article-title":"Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis","volume":"140","author":"Korosec","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jaci.2011.10.042","article-title":"IL-31 regulates differentiation and filaggrin expression in human organotypic skin models","volume":"129","author":"Cornelissen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/cea.12443","article-title":"Reduced filaggrin expression is accompanied by increased Staphylococcus aureus colonization of epidermal skin models","volume":"44","author":"van Drongelen","year":"2014","journal-title":"Clin Exp Allergy."},{"key":"B26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaci.2005.10.046","article-title":"IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis","volume":"117","author":"Bilsborough","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","article-title":"Correlation of IL-31 serum levels with severity of atopic dermatitis","volume":"122","author":"Raap","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1399-3038.2011.01241.x","article-title":"IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis","volume":"23","author":"Raap","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis","volume":"118","author":"Neis","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1600-0625.2010.01067.x","article-title":"Increased levels of serum IL-31 in chronic spontaneous urticaria","volume":"19","author":"Raap","year":"2010","journal-title":"Exp Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jaci.2012.11.008","article-title":"Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients","volume":"132","author":"Hartmann","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/jdv.12831","article-title":"Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels","volume":"30","author":"Altrichter","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1445-5994.2008.01673.x","article-title":"Chronic urticaria: the autoimmune paradigm","volume":"38","author":"Philpott","year":"2008","journal-title":"Intern Med J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e14794","DOI":"10.1371\/journal.pone.0014794","article-title":"IgE mediated autoallergy against thyroid peroxidase - a novel pathomechanism of chronic spontaneous urticaria?","volume":"6","author":"Altrichter","year":"2011","journal-title":"PLoS ONE"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/all.13215","article-title":"Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria","volume":"72","author":"Rauber","year":"2017","journal-title":"Allergy."},{"key":"B36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/imr.12632","article-title":"The role and relevance of mast cells in urticaria","volume":"282","author":"Church","year":"2018","journal-title":"Immunol Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"17797","DOI":"10.1038\/s41598-017-18187-z","article-title":"Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria","volume":"7","author":"Lin","year":"2017","journal-title":"Sci Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1067\/mai.2002.123236","article-title":"TH1\/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction","volume":"109","author":"Ying","year":"2002","journal-title":"J Allergy Clin Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12627","article-title":"Human mast cells and basophils-How are they similar how are they different?","volume":"282","author":"Varricchi","year":"2018","journal-title":"Immunol Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jaci.2010.05.047","article-title":"Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab","volume":"126","author":"Magerl","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jaci.2011.04.038","article-title":"Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase","volume":"128","author":"Maurer","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.7150\/thno.18304","article-title":"Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of Fc\u03b5RI-positive cells in the skin","volume":"7","author":"Metz","year":"2017","journal-title":"Theranostics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell Fce psilon RI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J Allergy Clin Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e12490","DOI":"10.1111\/dth.12490","article-title":"Therapy with anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"30","author":"Fioranelli","year":"2017","journal-title":"Dermatol Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/exd.13236","article-title":"Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody","volume":"27","author":"Oyama","year":"2018","journal-title":"Exp Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/vde.12715","article-title":"Proactive maintenance therapy of canine atopic dermatitis with the anti-IL-31 lokivetmab. can a monoclonal antibody blocking a single cytokine prevent allergy flares?","volume":"30","author":"Tamamoto-Mochizuki","year":"2019","journal-title":"Vet Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/vde.12364","article-title":"A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis","volume":"27","author":"Michels","year":"2016","journal-title":"Vet Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/vde.12478","article-title":"A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis","volume":"28","author":"Moyaert","year":"2017","journal-title":"Vet Dermatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jdermsci.2017.07.019","article-title":"Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE","volume":"87","author":"Salz","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2340\/00015555-2951","article-title":"Eosinophils are a major source of interleukin-31 in bullous pemphigoid","volume":"98","author":"R\u00fcdrich","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"5965492","DOI":"10.1155\/2017\/5965492","article-title":"The role of Intereukin-31 in pathogenesis of itch and its intensity in a course of bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Kulczycka-Siennicka","year":"2017","journal-title":"Biomed Res Int."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/j.1398-9995.2011.02570.x","article-title":"Basophil recruitment and activation in inflammatory skin diseases","volume":"66","author":"Ito","year":"2011","journal-title":"Allergy."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/j.1365-2133.2011.10748.x","article-title":"Successful management of severe infant bullous pemphigoid with omalizumab","volume":"166","author":"Dufour","year":"2012","journal-title":"Br J Dermatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","article-title":"Successful treatment of bullous pemphigoid with omalizumab","volume":"148","author":"London","year":"2012","journal-title":"Arch Dermatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2340\/00015555-2845","article-title":"Biological and clinical response to omalizumab in a patient with bullous pemphigoid","volume":"98","author":"Menzinger","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1111\/bjd.15924","article-title":"IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants","volume":"177","author":"Freire","year":"2017","journal-title":"Br J Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3389\/fimmu.2017.00484","article-title":"Eosinophils in autoimmune diseases","volume":"8","author":"Diny","year":"2017","journal-title":"Front Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2018.00407","article-title":"The autoimmune skin disease bullous pemphigoid: the role of mast cells in autoantibody-induced tissue injury","volume":"9","author":"Fang","year":"2018","journal-title":"Front Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2340\/00015555-1191","article-title":"IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis","volume":"92","author":"Nobbe","year":"2012","journal-title":"Acta Derm Venereol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00403-012-1293-6","article-title":"Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients","volume":"305","author":"Narbutt","year":"2013","journal-title":"Arch Dermatol Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jid.2017.12.029","article-title":"The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch","volume":"138","author":"Nattkemper","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.4049\/jimmunol.0900712","article-title":"Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells","volume":"184","author":"Niyonsaba","year":"2010","journal-title":"J Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"426","DOI":"10.5114\/pdia.2015.56097","article-title":"Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations","volume":"32","author":"Czarnecka-Operacz","year":"2015","journal-title":"Postepy Dermatol Alergol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3491798","DOI":"10.1155\/2018\/3491798","article-title":"Prevalence of pruritus in cutaneous lupus erythematosus: brief report of a multicenter, multinational cross-sectional study","volume":"2018","author":"Samotij","year":"2018","journal-title":"Biomed Res Int"},{"key":"B66","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00393-013-1274-y","article-title":"Serum levels of cytokines in systemic lupus erythematosus: association study in a chinese population","volume":"73","author":"Zhang","year":"2014","journal-title":"Z Rheumatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00296-016-3422-6","article-title":"The association of interleukin-31 polymorphisms with interleukin-31 serum levels and risk of systemic lupus erythematosus","volume":"36","author":"Huang","year":"2016","journal-title":"Rheumatol Int."},{"key":"B68","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2230.2004.01510.x","article-title":"Pruritus in adult dermatomyositis","volume":"29","author":"Shirani","year":"2004","journal-title":"Clin Exp Dermatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: the role of increased skin interleukin-31","volume":"179","author":"Kim","year":"2018","journal-title":"Br J Dermatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/bjd.16808","article-title":"Alopecia areata: a review of disease pathogenesis","volume":"179","author":"Rajabi","year":"2018","journal-title":"Br J Dermatol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01383\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:47:08Z","timestamp":1568940428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01383\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2019.01383"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01383","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,21]]},"article-number":"1383"}}